See final frame for AE reporting.

For HCPs in GB only.

Adverse events should be reported. Reporting forms and
information can be found at yellowcard.mhra.gov.uk.
Adverse events relating to CSL Seqirus products should also
be reported to Seqirus UK Limited on 01748 828816.

1. Seqirus Data on File, August 2023. SREF–17994.
2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.

Click for Prescribing Information

Click for Prescribing Information

GBR-AQIV-24-0062 | August 2024

Home
News
Sign Up
About
Sign in

Management
Health & Patient Care
Health Tech
Practice Operations
Recruit and Retain
Legal & Compliance
Live It

Follow us on Twitter
Follow us on Facebook
Follow us on LinkedIn
Email us

Search for:

HomeMediaqiv_01

qiv_01

qiv_01

Be the first to comment

Leave a Reply Cancel reply

You must be logged in to post a comment.

You may also enjoy

Heriot-Watt University’s Pioneering Solutions for Scotland’s Elderly Population

October 28, 2024
NEWS: NHS App to Include Unified Patient Records

October 28, 2024
Expert Insights on Biomarker Potential

October 25, 2024
NEWS: NHS England Chair Meddings to Step Down

October 25, 2024
The Human Touch: When Authenticity and AI Meet

October 24, 2024
Read Again: NHS Workforce: Challenges and Solutions

October 24, 2024
Getting to the Heart of Peer-to-Peer Recognition

October 24, 2024
NEWS: Starmer Calls For NHS Tech Overhaul

October 24, 2024

About us

Our brand has evolved and grown over the past 11 years – today we are a market leading healthcare publisher who produce monthly publications, websites, events and other targeted information, specifically for practice managers, GP partners and the other decision makers responsible for practice management

ADVERTISE WITH US

We here at Practice Business pride ourselves in creating solutions for suppliers to deliver their message in the most effective and interesting way possible. Our long-standing experience means the end result will be on message and read by the right people, every time. Get in touch today to find out how you can better reach your audience.

Advertising Options

OUR SISTER SITES

Our broader portfolio also includes a rich mix of education management titles – for state schools and academies, independent fee paying schools and free schools – we have something for everyone!

Education Executive

Contact us

Intelligent Media,
c/o Soho Works, Unit 4.1
The Tea Building
56 Shoreditch High Street London
E1 6JJ

Tel: 0203 794 8555
Fax: 0203 794 8554

Terms and Conditions

Follow us on Twitter
Follow us on Facebook
Follow us on LinkedIn
Email us

Copyright © 2024 | Practice Business | Intelligent Media Solutions | This site is intended for healthcare professionals only.

[su_column]

See final frame for AE reporting.

For HCPs in GB only.

Adverse events should be reported. Reporting forms and
information can be found at yellowcard.mhra.gov.uk.
Adverse events relating to CSL Seqirus products should also
be reported to Seqirus UK Limited on 01748 828816.

1. Seqirus Data on File, August 2023. SREF–17994.
2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.

Click for Prescribing Information

GBR-AQIV-24-0065 | August 2024

[/su_column]